Skip to Main content Skip to Navigation
Master Thesis

Les enjeux des biosimilaires, du modèle économique à la valorisation

Abstract : Like what happened in the classical pharmaceutical market, namely a weak productivity in R&D and the fallout of blockbusters patents, the biotechnology industry now faces the same problems and issues. The market authorization in 2006 for the first biosimilar Omnitrope® (somatropin) by Sandoz Laboratory, opens the way of a fierce competition between biosimilars manufacturers and companies of branded biologics. Some strategies of Product Lifecycle Management have been established in order to lead innovative products all along their life cycle to optimize their exploitation and struggle against the arrival of these lower cost therapies. In a perpetual quest of savings in healthcare, governments and payers put pressure on costs and give incentive for competition. Moreover, aging population in pharmemerging markets, where they have a low ability to pay, requires access to quality and lower cost treatments. Can biosimilars meet with these requirements? By their nature and manufacturing process, biosimilars are not identical to the reference biologics. What about the safety concerns? Which model for France?
Document type :
Master Thesis
Complete list of metadata

Cited literature [30 references]  Display  Hide  Download
Contributor : Jean-Hugues Morneau <>
Submitted on : Tuesday, July 7, 2015 - 3:54:59 PM
Last modification on : Tuesday, May 11, 2021 - 11:36:18 AM
Long-term archiving on: : Thursday, October 8, 2015 - 3:33:55 PM


  • HAL Id : dumas-01172631, version 1


Maxime Duffaud. Les enjeux des biosimilaires, du modèle économique à la valorisation. Sciences pharmaceutiques. 2015. ⟨dumas-01172631⟩



Record views


Files downloads